Application of anti-VEGF agents in the perioperative period of retinal vascular diseases
10.3760/cma.j.issn.2095-0160.2014.03.019
- VernacularTitle:抗VEGF药物在视网膜血管性疾病围手术期的应用
- Author:
Lei, JIANG
- Publication Type:Journal Article
- Keywords:
Vascular endothelial growth factor;
Perioperative period;
Retinal disease;
Glaucoma;
Neovascularization
- From:
Chinese Journal of Experimental Ophthalmology
2014;32(3):274-277
- CountryChina
- Language:Chinese
-
Abstract:
Vascular endothelial growth factor (VEGF) was proved to be closely associated with neovascularizational ocular diseases and a new therapeutic target.Anti-VEGF agents can inhibit the neovascularization and decrease the permeability of blood vessels.The application of anti-VEGF agents has revolutionized the treatment of these diseases.Ranibizumab has been approved to apply for the treatment of wAMD in China.In USA,it has been also approved to apply for the treatment of macular edema induced by diabetes or retinal vein occlusion.As off-label drug use,anti-VEGF agents also are used for other ocular neovascular diseases,such as proliferative diabetic retinopathy,other retinal vascular diseases and neovascular glaucoma.The clinical application of anti-VEGF agents as an adjunctive treatment modality to surgery has shown the obvious therapeutic effect,including minimizing the risk of complication and recrudescence in intraoperation and posteoperation.The perioperative research and application of anti-VEGF drugs including bevacizumab and ranibizumab in retinal vascular diseases were reviewed.
